ArticleCell insight2026
Isolation of Rhizoma Paridis saponins as novel entry inhibitors of Crimean-Congo hemorrhagic fever virus.
Article in Cell insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crimean-Congo hemorrhagic fever virus (CCHFV) is a highly pathogenic bunyavirus, causing Crimean-Congo hemorrhagic fever (CCHF) in humans with high morbidity and mortality. Currently, there are no licensed antiviral drugs or vaccines against CCHFV, emphasizing the critical need to develop novel antiviral agents. The entry process is the initial step during the viral life cycle, and has provided an attractive target for novel antiviral development. In the present study, we developed a high-throughput screening approach based on the CCHFV glycoprotein (Gn/Gc)-based HIV-1 pseudoviruses, in order to discover novel CCHFV entry inhibitors. As a pilot, a library consisting of 500 pre-purified fractions of traditional Chinese medicine was screened, and it was identified that multi-fractions of Rhizoma Paridis exhibited inhibitory effects against CCHFV entry. Next, bioactivity-guided isolation was performed and a range of Rhizoma Paridis saponins were characterized as potential anti-CCHFV actives. Moreover, the antiviral activities of both Rhizoma Paridis extracts and the saponin derivatives were validated by a cell-based assay using authentic viruses. Mechanistic studies further demonstrated that Rhizoma Paridis saponins act by targeting host factors. In summary, this study provides a promising new strategy for CCHF treatment that deserves further development in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.